DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
about
Satraplatin: leading the new generation of oral platinum agentsAn update on satraplatin: the first orally available platinum anticancer drug.Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancerSatraplatin: an orally available platinum analog for the treatment of cancer.Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.Novel metals and metal complexes as platforms for cancer therapySatraplatin for the therapy of castration-resistant prostate cancer.Clinical and pharmacokinetic evaluation of satraplatin.Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.Superhelical torsion controls DNA interstrand cross-linking by antitumor cis- diamminedichloroplatinum(II)Understanding the Interactions of High-Mobility Group of Protein Domain B1 with DNA Adducts Generated by Platinum Anticancer Molecules Using In Silico Approaches.
P2860
Q28972468-6E3CC9A7-5131-4688-A889-7CF609FE49A0Q34074919-82284081-BB9A-41CC-998E-09FBD1102865Q36135705-30D268CB-EC95-409B-A4F4-4ABE42710E5AQ36141013-681B49F3-E066-45D6-8223-8FFB99FBE2EFQ36295090-3B669928-1990-4596-B236-5BAFCE6A46E8Q36428631-C145E52E-6D35-47FA-B661-34BD7F606E10Q36532071-47D5C1D0-7AC5-4F75-A71A-64ABE8694719Q37136248-A1C88D64-4380-4458-8C9D-D4D0B5136456Q37137649-E16BBC92-0C9F-4350-8EE4-7AC0637D7F93Q37605845-754C4B98-82AE-46C1-BCE8-6684ADD6830DQ37958009-7A443320-20FE-4837-87BE-3023FB177AA0Q38347735-EDABEE25-CAAB-499A-BCC9-A9F5AA695EDEQ39692780-CF06280C-72D5-455E-9F8B-C3DCC2A1A7EBQ39717774-5F7AA5F2-5B27-4BD4-B29E-2071EDD4EF1DQ51295860-0ADB7FB3-2CD7-451F-A8CD-2A0B26F7B07D
P2860
DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
DNA-binding properties of nove ...... ovarian carcinoma cell lines.
@en
type
label
DNA-binding properties of nove ...... ovarian carcinoma cell lines.
@en
prefLabel
DNA-binding properties of nove ...... ovarian carcinoma cell lines.
@en
P2093
P2860
P356
P1476
DNA-binding properties of nove ...... ovarian carcinoma cell lines.
@en
P2093
B A Murrer
C F Barnard
K J Mellish
L R Kelland
P2860
P304
P356
10.1002/IJC.2910620612
P577
1995-09-01T00:00:00Z